A nasal spray administered in high-risk adult COVID-19 patients in India reduced viral load by 94 per cent within 24 hours and 99 per cent in 48 hours, according to the results of phase 3 trial of the ...
SAN FRANCISCO -- A new type of COVID-19 therapy is showing promise as a new tool to hijack the virus and slow down variants. It's a new weapon that could be added to the arsenal against COVID-19.
Covid Nasal Spray: A nasal spray administered in high-risk adult COVID-19 patients in India reduced viral load by 94 per cent within 24 hours and 99 per cent in 48 hours, according to the results of ...
The trial evaluated a seven-day treatment of NONS plus standard of care versus placebo nasal spray and standard care in patients with symptomatic COVID-19. (Representational image: Reuters) A nasal ...
SAN FRANCISCO -- A new type of COVID-19 therapy is showing promise as a new tool to hijack the virus and slow down variants. It's a new weapon that could be added to the arsenal against COVID-19.
A nasal spray administered in high-risk adult Covid-19 patients in India reduced viral load by 94 per cent within 24 hours and 99 per cent in 48 hours, according to the results of phase 3 trial of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback